William Blair analyst Myles Minter has maintained their bullish stance on BBIO stock, giving a Buy rating on March 12.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Myles Minter has given his Buy rating due to a combination of factors related to BridgeBio’s differentiated rare-disease portfolio and clear path toward profitability. He highlights the company’s positioning in transthyretin amyloid cardiomyopathy, where its ATTR-CM program, Attruby, is targeting a market already validated by tafamidis, which delivered multibillion-dollar annual sales and continues to expand.
In addition, he points to strong, recently disclosed data from the PROPEL-3 study of infigratinib in achondroplasia, emphasizing the appeal of an oral therapy backed by proportionality outcomes, not just height velocity. Minter also underscores the upside from earlier-stage orphan programs, including encaleret for ADH1 and BBP-418 for LGMD2I/R9, which together support a robust long-term growth thesis that, in his view, justifies a Buy recommendation.
In another report released on March 12, Jefferies also maintained a Buy rating on the stock with a $100.00 price target.
BBIO’s price has also changed moderately for the past six months – from $51.490 to $71.030, which is a 37.95% increase.